{"clinical_study": {"@rank": "19", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04315298"}, "id_info": {"org_study_id": "6R88-COV-2040", "nct_id": "NCT04315298"}, "brief_title": "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19", "official_title": "An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19", "sponsors": {"lead_sponsor": {"agency": "Regeneron Pharmaceuticals", "agency_class": "Industry"}, "collaborator": {"agency": "Sanofi", "agency_class": "Industry"}}, "source": "Regeneron Pharmaceuticals", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "Yes", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "Phase 2:\n\n      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative\n      to the control arm in adult patients hospitalized with severe COVID-19.\n\n      Phase 3:\n\n      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative\n      to the control arm in adult patients hospitalized with severe or critical COVID-19."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "March 16, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "March 16, 2021"}, "primary_completion_date": {"@type": "Anticipated", "#text": "March 16, 2021"}, "phase": "Phase 2/Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)"}, "primary_outcome": [{"measure": "Time to resolution of fever for at least 48 hours without antipyretics for 48 hours", "time_frame": "Up to day 29", "description": "Phase 2\nDefined as \u226436.6\u00b0C (axilla), \u226437.2\u00b0C (oral) or \u226437.8\u00b0C (rectal or tympanic)"}, {"measure": "Percentage of patients reporting each severity rating on a 6-point ordinal scale", "time_frame": "Day 15", "description": "Phase 3\n6-point Ordinal Scale:\nDeath\nHospitalized, on invasive mechanical ventilation or ECMO;\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\nHospitalized, requiring supplemental oxygen\nHospitalized, not requiring supplemental oxygen\nNot hospitalized"}], "secondary_outcome": [{"measure": "Time to improvement in oxygenation for at least 48 hours", "time_frame": "Up to day 29", "description": "Increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2"}, {"measure": "Mean change in the 6-point ordinal scale", "time_frame": "Up to day 29", "description": "6-point Ordinal Scale:\nDeath\nHospitalized, on invasive mechanical ventilation or ECMO;\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\nHospitalized, requiring supplemental oxygen\nHospitalized, not requiring supplemental oxygen\nNot hospitalized"}, {"measure": "Clinical status using the 6-point ordinal scale", "time_frame": "Up to day 29", "description": "6-point Ordinal Scale:\nDeath\nHospitalized, on invasive mechanical ventilation or ECMO;\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\nHospitalized, requiring supplemental oxygen\nHospitalized, not requiring supplemental oxygen\nNot hospitalized"}, {"measure": "Time to improvement in one category from admission using the 6-point ordinal scale", "time_frame": "Up to day 29", "description": "6-point Ordinal Scale:\nDeath\nHospitalized, on invasive mechanical ventilation or ECMO;\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\nHospitalized, requiring supplemental oxygen\nHospitalized, not requiring supplemental oxygen\nNot hospitalized"}, {"measure": "Time to resolution of fever for at least 48 hours without antipyretics by clinical severity", "time_frame": "Up to day 29", "description": "Defined as \u226436.6\u00b0C (axilla), \u226437.2\u00b0C (oral) or \u226437.8\u00b0C (rectal or tympanic)"}, {"measure": "Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels", "time_frame": "Up to day 29", "description": "Defined as \u226436.6\u00b0C (axilla), \u226437.2\u00b0C (oral) or \u226437.8\u00b0C (rectal or tympanic)"}, {"measure": "Time to improvement in oxygenation for at least 48 hours by clinical severity", "time_frame": "Up to day 29", "description": "Increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2"}, {"measure": "Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels", "time_frame": "Up to day 29", "description": "Increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2"}, {"measure": "Time to resolution of fever and improvement in oxygenation for at least 48 hours", "time_frame": "Up to day 29", "description": "Resolution of fever defined as \u226436.6\u00b0C (axilla), \u226437.2\u00b0C (oral) or \u226437.8\u00b0C (rectal or tympanic) Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2"}, {"measure": "Time to change in National Early Warning Score 2 (NEWS2) scoring system", "time_frame": "Up to day 29", "description": "NEWS2 consists of: Physiological Parameters: Respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), Use of air or oxygen, Systolic blood pressure (mmHg), Pulse (per minute), Consciousness, Temperature (\u00b0C)"}, {"measure": "Time to score of <2 maintained for 24 hours in NEWS2 scoring system", "time_frame": "Up to day 29", "description": "NEWS2 consists of: Physiological Parameters: Respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), Use of Air or oxygen, Systolic blood pressure (mmHg), Pulse (per minute), Consciousness, Temperature (\u00b0C)"}, {"measure": "Mean change in NEWS2 scoring system", "time_frame": "Up to day 29", "description": "NEWS2 consists of: Physiological Parameters: Respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), Use of air or oxygen, Systolic blood pressure (mmHg), Pulse (per minute), Consciousness, Temperature (\u00b0C)"}, {"measure": "Number of days with fever", "time_frame": "Up to day 29", "description": "Defined as >36.6\u00b0C (axilla), >37.2\u00b0C (oral) or >37.8\u00b0C (rectal or tympanic)"}, {"measure": "Number of patients alive off oxygen", "time_frame": "Day 29"}, {"measure": "Number of days of resting respiratory rate >24 breaths/min", "time_frame": "Up to day 29"}, {"measure": "Number of days with hypoxemia", "time_frame": "Up to day 29"}, {"measure": "Number of days of supplemental oxygen use", "time_frame": "Up to day 29"}, {"measure": "Time to saturation \u226594% on room air", "time_frame": "Up to day 29"}, {"measure": "Number of ventilator free days in the first 28 days", "time_frame": "Baseline to day 29"}, {"measure": "Number of patients requiring initiation of mechanical ventilation", "time_frame": "Up to day 29"}, {"measure": "Number of patients requiring non-invasive ventilation", "time_frame": "Up to day 29"}, {"measure": "Number of patients requiring the use of high flow nasal cannula", "time_frame": "Up to day 29"}, {"measure": "Number of patients admitted into an intensive care unit (ICU)", "time_frame": "Up to day 29"}, {"measure": "Number of days of hospitalization among survivors", "time_frame": "Up to day 29"}, {"measure": "Number of deaths due to any cause", "time_frame": "Up to day 60"}, {"measure": "Incidence of serious adverse events", "time_frame": "Up to day 60"}, {"measure": "Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection", "time_frame": "Up to day 29"}, {"measure": "Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia", "time_frame": "Up to day 60"}, {"measure": "Incidence of hypersensitivity reactions", "time_frame": "Up to day 29"}, {"measure": "Incidence of infusion reactions", "time_frame": "Up to day 29"}, {"measure": "Incidence of gastrointestinal perforation", "time_frame": "Up to day 60"}, {"measure": "White blood cell count", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Hemoglobin levels", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Platelet count", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Creatinine levels", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Total bilirubin level", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Alanine aminotransferase level", "time_frame": "Up to day 29 if still hospitalized"}, {"measure": "Aspartate aminotransferase level", "time_frame": "Up to day 29 if still hospitalized"}], "number_of_arms": "3", "enrollment": {"@type": "Anticipated", "#text": "400"}, "condition": "COVID-19", "arm_group": [{"arm_group_label": "Sarilumab high dose", "arm_group_type": "Experimental"}, {"arm_group_label": "Sarilumab low dose", "arm_group_type": "Experimental"}, {"arm_group_label": "Placebo", "arm_group_type": "Placebo Comparator"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Sarilumab", "description": "Single intravenous (IV) dose of sarilumab", "arm_group_label": ["Sarilumab high dose", "Sarilumab low dose"], "other_name": ["Kevzara\u00ae", "REGN88", "SAR153191"]}, {"intervention_type": "Drug", "intervention_name": "Placebo", "description": "Single intravenous (IV) dose of placebo to match sarilumab administration", "arm_group_label": "Placebo"}], "eligibility": {"criteria": {"textblock": "Key Inclusion Criteria:\n\n          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction\n             (PCR) or other commercial or public health assay\n\n          -  Hospitalized with illness of any duration with evidence of pneumonia and severe\n             disease, critical disease, or multi-system organ dysfunction at baseline\n\n          -  Ability to provide informed consent signed by study patient or legally acceptable\n             representative\n\n          -  Willingness and ability to comply with study-related procedures/assessments\n\n        Key Exclusion Criteria:\n\n          -  In the opinion of the investigator, unlikely to survive for >48 hours from screening\n\n          -  Presence of any of the following abnormal laboratory values at screening: absolute\n             neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase (AST) or alanine\n             aminotransferase (ALT) greater than 5 x upper limit of normal (ULN), platelets <50,000\n             per mm3\n\n          -  Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors\n             (JAKi) in the past 30 days or plans to receive during the study period\n\n          -  Current treatment with conventional synthetic disease-modifying antirheumatic drugs\n             (DMARDs)/immunosuppressive agents\n\n          -  Use of chronic oral corticosteroids for a non-COVID-19-related condition in a dose\n             higher than prednisone 10 mg or equivalent per day\n\n          -  History of, or current autoimmune or inflammatory systemic or localized disease(s)\n             other than rheumatoid arthritis\n\n          -  Known active tuberculosis (TB), history of incompletely treated TB, suspected or known\n             extrapulmonary TB, suspected or known systemic bacterial or fungal infections\n\n          -  Patients who have received immunosuppressive antibody therapy within the past 5\n             months, including intravenous immunoglobulin or plans to receive during the study\n             period\n\n          -  Participation in any clinical research study evaluating an investigational product\n             (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the\n             screening visit (The use of remdisivir in the context of a single-arm remdisivir\n             compassionate use protocol is permitted)\n\n          -  Any physical examination findings and/or history of any illness that, in the opinion\n             of the study investigator, might confound the results of the study or pose an\n             additional risk to the patient by their participation in the study\n\n        NOTE: Other protocol defined inclusion / exclusion criteria may apply"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Clinical Trial Management", "role": "Study Director", "affiliation": "Regeneron Pharmaceuticals"}, "overall_contact": {"last_name": "Clinical Trials Administrator", "phone": "844-734-6643", "email": "clinicaltrials@regeneron.com"}, "location": [{"facility": {"name": "Regeneron Study Site", "address": {"city": "Los Angeles", "state": "California", "zip": "90095", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Palo Alto", "state": "California", "zip": "94304", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Sacramento", "state": "California", "zip": "95817", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Coral Gables", "state": "Florida", "zip": "33146", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Decatur", "state": "Georgia", "zip": "30033", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Marietta", "state": "Georgia", "zip": "30060", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Baltimore", "state": "Maryland", "zip": "21205", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Boston", "state": "Massachusetts", "zip": "02111", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regneron Study Site", "address": {"city": "Boston", "state": "Massachusetts", "zip": "02215", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Detroit", "state": "Michigan", "zip": "48236", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Edison", "state": "New Jersey", "zip": "08820", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Hackensack", "state": "New Jersey", "zip": "07601", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Livingston", "state": "New Jersey", "zip": "07039", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Morristown", "state": "New Jersey", "zip": "07960", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Neptune", "state": "New Jersey", "zip": "07753", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Newark", "state": "New Jersey", "zip": "07112", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Teaneck", "state": "New Jersey", "zip": "07666", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Bronx", "state": "New York", "zip": "10451", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site 1", "address": {"city": "Bronx", "state": "New York", "zip": "10461", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site 2", "address": {"city": "Bronx", "state": "New York", "zip": "10461", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Bronx", "state": "New York", "zip": "10467", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Brooklyn", "state": "New York", "zip": "11219", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Elmhurst", "state": "New York", "zip": "11373", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Facility 2", "address": {"city": "Manhasset", "state": "New York", "zip": "11030", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site 1", "address": {"city": "Manhasset", "state": "New York", "zip": "11030", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10003", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10016", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site 1", "address": {"city": "New York", "state": "New York", "zip": "10025", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site 2", "address": {"city": "New York", "state": "New York", "zip": "10025", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10029", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10032", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10037", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "New York", "state": "New York", "zip": "10065", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Stony Brook", "state": "New York", "zip": "11794", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Murray", "state": "Utah", "zip": "84107", "country": "United States"}}, "status": "Not yet recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Everett", "state": "Washington", "zip": "98201", "country": "United States"}}, "status": "Recruiting"}, {"facility": {"name": "Regeneron Study Site", "address": {"city": "Renton", "state": "Washington", "zip": "98055", "country": "United States"}}, "status": "Recruiting"}], "location_countries": {"country": "United States"}, "verification_date": "March 2020", "study_first_submitted": "March 15, 2020", "study_first_submitted_qc": "March 17, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 19, 2020"}, "last_update_submitted": "March 26, 2020", "last_update_submitted_qc": "March 26, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 30, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": ["COVID-19", "SARS-COV-2", "coronavirus", "IL-6", "sarilumab", "acute respiratory distress syndrome", "treatment"], "patient_data": {"sharing_ipd": "Yes", "ipd_description": "All IPD that underlie publicly available results will be considered for sharing", "ipd_info_type": ["Study Protocol", "Statistical Analysis Plan (SAP)", "Informed Consent Form (ICF)", "Clinical Study Report (CSR)", "Analytic Code"], "ipd_time_frame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification", "ipd_access_criteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).", "ipd_url": "https://errs.regeneron.com/external"}}}